京基智農(000048.SZ):年出欄50萬頭生豬養殖產業鏈項目擬落户高要祿步
格隆匯12月18日丨京基智農(000048.SZ)宣佈,公司於2020年12月17日與廣東省肇慶市高要區祿步鎮人民政府簽署關於投資建設生豬養殖產業鏈項目的框架協議。該項目名稱為年出欄50萬頭生豬養殖產業鏈項目。
項目內容為新建飼料生產、生豬養殖、生豬屠宰、食品加工與流通以及其他配套設施。項目將分兩期進行,其中一期項目包括飼料生產、生豬養殖及其他必要配套設施;二期項目包括生豬養殖、生豬屠宰、食品加工與冷鏈物流及其他必要配套設施。
該項目計劃分兩期總投資約13億元民幣(含流動資金),其中一期項目計劃總投資約11.5億元,二期項目計劃總投資約1.5億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.